期刊文献+

绝经早期激素替代治疗的临床观察 被引量:2

下载PDF
导出
摘要 目的在绝经早期应用激素替代(HT)治疗过程中,通过检测超敏C反应蛋白(hsCRP)及血脂的变化,探讨其对心血管的影响,预测冠心病的危险性。方法对34例绝经早期妇女采用激素替代治疗一年,比较用药前后血脂及超敏C反应蛋白的变化。结果 HT治疗1年后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)、hsCRP均下降,高密度脂蛋白(HDL-C)升高,与治疗前比较,差异有统计学意义(P<0.05)。结论绝经早期接受激素替代治疗可以预防血脂紊乱,减少冠心病的发生。
作者 王红延
出处 《心脑血管病防治》 2010年第3期198-200,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
  • 相关文献

参考文献5

二级参考文献41

  • 1徐苓,赵珩,葛秦生.围绝经期的流行病学调查[J].生殖医学杂志,1993,2(1):23-27. 被引量:105
  • 2卫生部继续医学教育委员会.女性生殖内分泌性激素补充疗法[M].北京:北京医科大学、中国协和医科大学联合出版社,1999.84-90.
  • 3叶任高,陆再英,主编.内科学[M].第6版.北京:人民卫生出版社,2005,28-30.
  • 4Hulley SB,Grady D.The WHI estrogen-alone trial-do things look any better?JAMA,2004,291(14):1769-1771
  • 5Hully S,Grady D,Bush T,et al.For the Heart and Estrogen/Progestin Replacement Study Research Group.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.JAMA,1998,280:605-613
  • 6Rossouw JE,Anderson GL,Prentice RL,et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women's Health Initiative randomized controlled trial.JAMA,2002,288:321-333
  • 7Manson JE,Hsia J,Johnson KC,et al.Estrogen plus progestin and the risk of coronary heart disease.N Eng J Med,2003,349:523-534
  • 8Chlebowski RT,Hendrix SL,Langer RD,et al.Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women the Women's Health Initiative randomized controlled trial.J Am Med Assoc,2003,238:3243-3253
  • 9Million Women Study Collaborators.Breast cancer and hormone-replacement therapy in the Million Women Study.Lancet,2003,362:419-427
  • 10Stevenson JC.Cardiovascular effects of oestrogens.J Steroid Biochem Mol Biol,2000,74:387-393

共引文献81

同被引文献31

  • 1沈旭娜,冯泽蛟,李苑艳.腹腔镜联合药物治疗子宫内膜异位症的疗效观察[J].江西医药,2006,41(8):586-588. 被引量:4
  • 2子宫内膜异位症的诊断与治疗规范[J].中华妇产科杂志,2007,42(9):645-648. 被引量:563
  • 3Sturdee DW, Pines A. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric, 2011, 14(3):302-20.
  • 4Kupperman HS, Wetchler BB, Blatt MH, et al. Contempo- rary therapy of the menopausal syndrome. JAMA, 1959, 171 (11):1627-37.
  • 5Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas, 1996, 24(3): 161-75.
  • 6Delfin T, Christopher JH, Khunying KL, et al. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan- Asia menopause (PAM) study. Maturitas, 2005, 52(1):35- 51.
  • 7Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomo- tor symptoms and vaginal atrophy with lower doses of con- jugated equine estrogens and medroxyprogesterone acetate. Fertil Steril, 2001, 75(6): 1065-70.
  • 8Akhila V, Pratapkumar. A comparison of transdcrmal and oral HRT for menopausal symptom control. Int J Fertil Womens Med, 2006, 51(2):64-9.
  • 9Jewelewicz 1L New developments in topical estrogen therapy. Fertil Steril, 1997, 67(1):1-12.
  • 10Fait T, Vrablik M, Zizka Z, et al. Effect of early onset of transdermal and oral estrogen therapy on the lipid profile: a prospective study with cross-over design. Ceska Gynekol, 2006, 71(3):226-30.

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部